What peeves me off is that if you minus the $6.2 mil cash from the deal and the $1.5 mil left at the end of the quarter from the market cap, then the value of our products is $9.25 mil. That is bloody ludicrous to be honest.
To have a drug that is progressing into phase 3 now with a deal (maybe not the best deal, but A DEAL!!!), another going to phase 2 and potential for early compassionate use, allowing for revenue generation, plus 1101, and all we get for them is a bloody value of $9.25 mil is (insert expletive here) BS.
The mindset of aussies and kiwis (to an extent. Have to add them as I'm one) towards biotechs is so immature to say the least. Biotechs like all pharma stocks are very long term stocks. It takes about 17 years on average to get a drug from conception to commercialisation. It's something I mentioned a couple years back (maybe not on this site). But to dump the stock after the 12 years of decent progress in terms of trials etc, and now a deal, the company has made is bloody annoying.
But the fault also, I say for a large part, lays with management. This is a stock that should be having the hell promoted out of it, considering everything it has achieved. PR people have been hired, yet sweet (insert expletive here) all has been achieved on that front. I've only finished uni, but I know that I could do a much better job at PR for this company than what has been seen. Word of mouth/word of mouse (digital era) and networking could play a huge role here, if you want cheap PR. But nope you barely see anything.
Personally I would like management to be doing far more PR on this. With decent PR this stock would be nowhere near the level it sits at now as there would be more holders of this. We know the product is good, but its being wrapped inside of a package smeared with unholy substances. One thing the company could do is engage investors and the wider public more, particularly through social media. Facebook/Twitter etc, you know is a very cheap source of advertising. Keeping investors in the loop even with little things is enough to help keep the faith.
But all in all, $9.25 valuation of assets considering how they've come is ridiculous. Management (particular on the PR front) must shoulder the blame.
Perhaps shareholders should petition for someone/a couple of new faces on the board to push this stock to the wider public, may it be as an investment or just getting the company out there and getting people familiar with it. I know Megagene years ago tried and failed but considering everything thats happened since, shareholders will definitely have more sway now.
I'm still a believer in the product, not so much the marketing of it, but the product and will in time buy more when I have money. Rant over.
ANP Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
